EPSILON-ADVANCED
2.2.2024 17:28:29 CET | Business Wire | Press release
Epsilon Advanced Materials (EAM) today finalized the acquisition of a lithium-ion phosphate (LFP) cathode active material technology center in Moosburg, Germany, making it the first global company capable of providing manufacturers with both cathode and anode materials for lithium-ion batteries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201488246/en/
Vikram Handa, Managing Director, Epsilon Advanced Materials (center), stands with employees at the lithium-ion phosphate (LFP) cathode active material technology center in Moosburg, Germany. Epsilon Advanced Materials acquired the facility, positioning the company to lead the electric vehicle battery industry in cathode material manufacturing. (Photo: Business Wire)
With the purchase, EAM is poised to make India the first country in Asia outside of China to manufacture LFP cathode materials. Approximately 70% of cathode materials, and 100% of LFP cathode, for lithium-ion batteries are currently produced in China.
“This acquisition reaffirms our commitment to delivering cutting-edge solutions to the evolving EV battery market,” said Vikram Handa, managing director of EAM. "The advanced technology center in Moosburg strategically positions us to lead the industry in cathode material manufacturing.”
Acquiring the cathode active material technology center from Johnson Matthey solidifies EAM’s position as a global EV battery materials provider, with the potential to reshape the landscape of electric mobility by reducing the battery market’s reliance on China.
Epsilon previously announced a $1.1 billion investment for the establishment of an anode battery materials manufacturing facility in Bellari, Karnataka, India. EAM also plans to build a $650 million graphite anode material manufacturing facility in Brunswick County, North Carolina, U.S. and is investing Euro 600 million to develop a graphite processing facility in Vaasa, Finland.
"We are proud to announce that EAM is now ready to go to market with a proven high-performance cathode active material, marking a significant leap forward in our capabilities,” said EAM CEO Sunit Kapur “Integrating the cathode expertise from the Moosburg technology center with our anode business uniquely positions us to deliver comprehensive solutions to customers, delivering anode and cathode to empower them to optimize the performance of their batteries.”
Battery manufacturers are increasingly transitioning to LFP cathode, which has a longer life span, offers improved discharge and charge efficiency, provides better performance in higher temperatures and is less expensive compared to other cathode materials, such as nickel and cobalt, and it also is maintenance-free, extremely safe and lightweight.
EAM is scheduled to break ground on its facility in India in 2024 to build a large-scale customer qualification plant in 2025, which will scale up to 100,000 tons by 2030.
The Moosburg facility, which employs approximately 25 people in its R&D and operations greatly reduces EAM’s technology development and scale-up timeframe. The center is equipped to produce LFP and lithium manganese iron phosphate (LMFP) cathode in small laboratory-scale batches to up pilot-scale material. It features a versatile pilot customer qualification plant designed to validate new materials and utilizes a Hydrothermal process that provides a cleaner metal processing solution, which results in a more environmentally friendly battery-metals supply chain.
About Epsilon Advanced Materials
Epsilon Advanced Materials is at the forefront of battery material solutions, producing high-caliber, innovative, and environmentally conscious lithium-ion battery (LiB) materials. Founded in 2018 and headquartered in Mumbai, Epsilon's mission resonates with supporting the global battery industry's transition to clean and green energy. With a significant presence spanning Europe, North America, and South-East Asia, Epsilon continues to set industry benchmarks. https://www.epsilonam.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201488246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom